ArticleJournal of neural transmission (Vienna, Austria : 1996)2017
Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Home-Based Exercise to Improve Motor Functions, Cognitive Functions, and Quality of Life in People with Huntington's Disease: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Novel Therapeutic Insights Into Alzheimer's Disease: Glymphatic System and Meningeal Lymphatic Vessels.Aging cell · 2026Review
- CSF phospho-tau levels at Parkinson's disease onset predict the risk for development of motor complications.Journal of neurology · 2025Article
- Review
- Association between cerebrospinal fluid pressure and cognition in patients with Alzheimer's disease and Lewy body dementia.BMC neurology · 2024Article
- Detection of APP gene recombinant in human blood plasma.Scientific reports · 2023Article
- Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters.Frontiers in neurology · 2022Article
- Design of an Innovative Methodology for Cerebrospinal Fluid Analysis: Preliminary Results.Sensors (Basel, Switzerland) · 2021Article
- Exosomal Aβ-Binding Proteins Identified by "In Silico" Analysis Represent Putative Blood-Derived Biomarker Candidates for Alzheimer´s Disease.International journal of molecular sciences · 2021Article
- How Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging.Journal of Alzheimer's disease reports · 2021Article
- Research on the Glial-Lymphatic System and Its Relationship With Alzheimer's Disease.Frontiers in neuroscience · 2021Review
- Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease.Drug development research · 2020Review
- Development of an Immunoassay for the Detection of Amyloid Beta 1-42 and Its Application in Urine Samples.Journal of immunology research · 2020Article
- Association between physical activity and dementia's risk factors in patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
- Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.Journal of neural transmission (Vienna, Austria : 1996) · 2018Article
- Diagnosis of neurodegenerative dementia: where do we stand, now?Annals of translational medicine · 2018Review
- Association of Difference in Coronary Sinus Diameter by Computed Tomographic Angiography Between Patients in and Not in Stable Atherosclerotic Plaque(S).Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Comparison of the Efficacy, Side Effects, and Cost of Modafinil and Intranasal Mometasone Furoate in Obstructive Sleep Apnea-Hypopnea Syndrome: A Preliminary Clinical Study.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experimental data suggest that the cerebrospinal fluid (CSF) dynamic is involved in the clearance of beta-amyloid, a key event in the pathogenesis of Alzheimer's disease (AD). At this regard no evidence still exists in vivo. In this study we explored the relationships between CSF pressure and AD pathology, as measured with CSF core biomarkers. We enrolled 16 patients with probable AD and 21 controls, collecting demographics, clinical data, CSF opening pressure and CSF levels of beta-amyloid-42 fragment (Aβ42), total-tau (t-tau), phosphorylated-tau-181 (p-tau), albumin and albumin ratio. Differences between the groups were calculated with non-parametric tests, while correlations among all parameters were separately calculated with Spearman's test in each group. The groups significantly differed in biomarkers' concentration with lower Aβ42, and higher t-tau and p-tau in AD patients. Moreover, CSF pressure was significantly lower in AD group (11.0 ± 2.8 vs. 13.3 ± 3.0 mmHg, p < 0.05) and directly correlated with Aβ42 levels (R = 0.512; p < 0.05), but not with other biomarkers or parameters. No significant correlations emerged for biomarkers in control group. AD patients exhibit low CSF pressure whose values are directly and selectively related to CSF Aβ42 levels. This interesting correlation may confirm in vivo the association between CSF dynamic and beta-amyloid metabolism occurring in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.